The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) obesity medications like semaglutide (Wegovy) and tirzepatide (Zepbound), challenging a two-decade-old law and facing probable opposition from the incoming Trump administration.

In its announcement, the Biden administration called anti-obesity medicines “life-saving drugs,” noting that they can also prevent diabetes.

Millions of Americans could soon have access to weight-loss medications that some have called "miracle drugs."

The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and Medicaid. However, the move would have to be approved by the new Trump administration.

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.